QC
NBIX icon

QCM Cayman’s Neurocrine Biosciences NBIX Stock Holding History

QCM Cayman’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-6,594
Closed -$300K – 302
2016
Q2 		$300K Buy
+6,594
New +$304K 0.13% 129
2015
Q4 		– Sell
-7,130
Closed -$284K – 228
2015
Q3 		$284K Buy
+7,130
New +$345K 0.09% 126

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

QCM Cayman's NBIX Position: Q3 2016 in Review

QCM Cayman sold out of Neurocrine Biosciences (NBIX) in Q3 2016, closing a stake of 6,594 shares — an estimated $300K sold.

QCM Cayman first reported a position in NBIX in Q3 2015 and held it in 2 quarters. The position peaked at $300K in Q2 2016. 244 funds tracked by Wall St. Rank hold NBIX as of Q3 2016.

  • QCM Cayman reported no remaining Neurocrine Biosciences position as of Q3 2016 after selling out during the quarter.
  • QCM Cayman sold 6,594 Neurocrine Biosciences shares in Q3 2016, an estimated $300K.
  • QCM Cayman first reported a position in Neurocrine Biosciences in Q3 2015 and held it in 2 quarters.
  • QCM Cayman's Neurocrine Biosciences position peaked at $300K in Q2 2016.
  • 244 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2016.

Based on QCM Cayman's 13F filing for Q3 2016, filed 14 Nov 2016.